NCT03552029 - Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Quizartinib

20 or 30 mg tablets for oral administration

DRUG

Milademetan

5, 20, 80 or 200 mg capsules for oral administration

DRUG

Milademetan

5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized

Trial Locations (8)

Roswell Park Comprehensive Cancer Center, Buffalo

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia

Duke University Cancer Center, Durham

Rogel Cancer Center, University of Michigan, Ann Arbor

University of Kansas Cancer Center, Fairway

MD Anderson Cancer Center, Houston

Ronald Reagan Medical Center, UCLA, Los Angeles

Yale Cancer Center, New Haven